MX2022001743A - Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma. - Google Patents
Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.Info
- Publication number
- MX2022001743A MX2022001743A MX2022001743A MX2022001743A MX2022001743A MX 2022001743 A MX2022001743 A MX 2022001743A MX 2022001743 A MX2022001743 A MX 2022001743A MX 2022001743 A MX2022001743 A MX 2022001743A MX 2022001743 A MX2022001743 A MX 2022001743A
- Authority
- MX
- Mexico
- Prior art keywords
- solid state
- state forms
- dronaftalen
- tetrahi
- neopentylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se relaciona con: a) formas en estado sólido de las sales bromhidrato del Compuesto 1; b) composiciones farmacéuticas que comprenden una o más formas en estado sólido de las sales bromhidrato del Compuesto 1, y, opcionalmente, un portador farmacéuticamente aceptable; c) métodos de tratamiento de tumores o de cánceres por medio de la administración de una o más formas en estado sólido de las sales bromhidrato del Compuesto 1 a un sujeto en necesidad de ello; y d) métodos para la preparación de las formas en estado sólido del Compuesto 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/045948 WO2021029854A1 (en) | 2019-08-09 | 2019-08-09 | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001743A true MX2022001743A (es) | 2022-05-10 |
Family
ID=67734850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001743A MX2022001743A (es) | 2019-08-09 | 2019-08-09 | Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4010322B1 (es) |
| JP (1) | JP7608435B2 (es) |
| KR (1) | KR102772889B1 (es) |
| CN (1) | CN114555562A (es) |
| AR (1) | AR119614A1 (es) |
| AU (1) | AU2019461090A1 (es) |
| BR (1) | BR112022002392A2 (es) |
| CA (1) | CA3150424A1 (es) |
| CO (1) | CO2022002731A2 (es) |
| DK (1) | DK4010322T3 (es) |
| IL (1) | IL290428A (es) |
| LT (1) | LT4010322T (es) |
| MX (1) | MX2022001743A (es) |
| PE (1) | PE20221252A1 (es) |
| PT (1) | PT4010322T (es) |
| WO (1) | WO2021029854A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115916188A (zh) * | 2020-03-13 | 2023-04-04 | 斯普林渥克斯治疗有限公司 | 尼罗司他与bcma定向疗法的组合疗法及其用途 |
| TWI905452B (zh) | 2021-09-01 | 2025-11-21 | 美商斯普林渥克斯治療有限公司 | 尼羅司他（ｎｉｒｏｇａｃｅｓｔａｔ）之合成 |
| US11504354B1 (en) * | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
| US20240408067A1 (en) | 2021-11-23 | 2024-12-12 | Teva Pharmaceuticals International Gmbh | Solid state forms of nirogacestat salts |
| WO2023174390A1 (zh) * | 2022-03-17 | 2023-09-21 | 苏州科睿思制药有限公司 | 尼罗司他二氢溴酸盐的晶型及其制备方法和用途 |
| KR20250155587A (ko) | 2023-03-09 | 2025-10-30 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 니로가세스타트 디히드로브로마이드의 결정형, 및 이의 제조 방법 및 이의 용도 |
| WO2026018210A1 (en) | 2024-07-19 | 2026-01-22 | Assia Chemical Industries Ltd. | Solid state forms of nirogacestat dihydrochloride salt |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE399155T1 (de) * | 2004-03-23 | 2008-07-15 | Pfizer Prod Inc | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen |
| WO2015092614A1 (en) * | 2013-12-20 | 2015-06-25 | Pfizer Inc. | Activating notch alterations in breast cancer |
| WO2018045273A2 (en) * | 2016-09-02 | 2018-03-08 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| WO2019053727A1 (en) * | 2017-09-18 | 2019-03-21 | Ramot At Tel-Aviv University Ltd. | REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH |
-
2019
- 2019-08-09 PT PT197585896T patent/PT4010322T/pt unknown
- 2019-08-09 PE PE2022000224A patent/PE20221252A1/es unknown
- 2019-08-09 DK DK19758589.6T patent/DK4010322T3/da active
- 2019-08-09 CA CA3150424A patent/CA3150424A1/en active Pending
- 2019-08-09 AU AU2019461090A patent/AU2019461090A1/en active Pending
- 2019-08-09 EP EP19758589.6A patent/EP4010322B1/en active Active
- 2019-08-09 LT LTEPPCT/US2019/045948T patent/LT4010322T/lt unknown
- 2019-08-09 IL IL290428A patent/IL290428A/en unknown
- 2019-08-09 MX MX2022001743A patent/MX2022001743A/es unknown
- 2019-08-09 JP JP2022508525A patent/JP7608435B2/ja active Active
- 2019-08-09 KR KR1020227007648A patent/KR102772889B1/ko active Active
- 2019-08-09 CN CN201980100044.2A patent/CN114555562A/zh active Pending
- 2019-08-09 WO PCT/US2019/045948 patent/WO2021029854A1/en not_active Ceased
- 2019-08-09 BR BR112022002392A patent/BR112022002392A2/pt unknown
-
2020
- 2020-08-06 AR ARP200102241A patent/AR119614A1/es unknown
-
2022
- 2022-03-09 CO CONC2022/0002731A patent/CO2022002731A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4010322A1 (en) | 2022-06-15 |
| AR119614A1 (es) | 2021-12-29 |
| JP7608435B2 (ja) | 2025-01-06 |
| KR102772889B1 (ko) | 2025-02-26 |
| CA3150424A1 (en) | 2021-02-18 |
| CN114555562A (zh) | 2022-05-27 |
| LT4010322T (lt) | 2025-12-29 |
| JP2022553479A (ja) | 2022-12-23 |
| KR20220062510A (ko) | 2022-05-17 |
| CO2022002731A2 (es) | 2022-05-20 |
| WO2021029854A1 (en) | 2021-02-18 |
| PT4010322T (pt) | 2025-12-16 |
| BR112022002392A2 (pt) | 2022-04-26 |
| AU2019461090A1 (en) | 2022-03-17 |
| EP4010322B1 (en) | 2025-11-05 |
| DK4010322T3 (da) | 2025-12-15 |
| PE20221252A1 (es) | 2022-08-16 |
| IL290428A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025004371A (es) | Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4- tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma | |
| MX2022001743A (es) | Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma. | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| JOP20210241A1 (ar) | مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| ZA202103587B (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| CL2017002022A1 (es) | Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| MX2020013116A (es) | Sales y cristales novedosos. | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| MX2018016330A (es) | Combinaciones para tratamiento del cáncer. | |
| MX2021002981A (es) | Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30). | |
| NZ752587A (en) | Lsd1 inhibitors and medical uses thereof | |
| CO2021010493A2 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| MX2024006074A (es) | Inhibidor de parp1 selectivo y aplicacion del mismo. | |
| AR112103A1 (es) | Compuestos para el tratamiento de tnbc | |
| UY40235A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| SV2011004017A (es) | Tratamiento del cancer de pancreas | |
| UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
| BR112022005723A2 (pt) | Compostos de indol carboxamida e seu uso para o tratamento de infecções micobacterianas |